119 related articles for article (PubMed ID: 38216370)
21. Gallium-68-prostate-specific membrane antigen (
van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
[TBL] [Abstract][Full Text] [Related]
22. Factors Predicting Metastatic Disease in
Chiu LW; Lawhn-Heath C; Behr SC; Juarez R; Perez PM; Lobach I; Bucknor MD; Hope TA; Flavell RR
J Nucl Med; 2020 Dec; 61(12):1779-1785. PubMed ID: 32303599
[TBL] [Abstract][Full Text] [Related]
23. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
Ekmekcioglu O; Yavuzsan AH; Arican P; Kirecci SL
J Cancer Res Ther; 2021; 17(6):1351-1357. PubMed ID: 34916365
[TBL] [Abstract][Full Text] [Related]
24. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
25. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
[TBL] [Abstract][Full Text] [Related]
26. The Relationship between the SUVmax Value Obtained in Ga-68 PSMA PET/CT and Lactate Dehydrogenase and Alkaline Phosphatase in Prostate Cancer.
Ertürk SA; Şalk İ; Yücel B; Ulaş Babacan Ö; Hasbek Z
Arch Esp Urol; 2022 Aug; 75(6):552-558. PubMed ID: 36138505
[TBL] [Abstract][Full Text] [Related]
27. Uptake of
Malaspina S; Taimen P; Kallajoki M; Oikonen V; Kuisma A; Ettala O; Mattila K; Boström PJ; Minn H; Kalliokoski K; Postema EJ; Miller MP; Scheinin M
Cancer Biother Radiopharm; 2022 Apr; 37(3):205-213. PubMed ID: 34962139
[No Abstract] [Full Text] [Related]
28.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
[TBL] [Abstract][Full Text] [Related]
30. Clinical insignificance of [
Arnfield EG; Thomas PA; Roberts MJ; Pelecanos AM; Ramsay SC; Lin CY; Latter MJ; Garcia PL; Pattison DA
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4495-4507. PubMed ID: 34136957
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic accuracy of [
Mingels C; Bohn KP; Rominger A; Afshar-Oromieh A; Alberts I
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2436-2444. PubMed ID: 35067735
[TBL] [Abstract][Full Text] [Related]
32. Head-to-Head Comparison of
Han T; Quan Z; Wang M; Meng X; Zhang M; Ye J; Li G; Wang J; Kang F
Mol Pharm; 2023 Nov; 20(11):5646-5654. PubMed ID: 37862042
[TBL] [Abstract][Full Text] [Related]
33. Combined Utility of
Kalapara AA; Ballok ZE; Ramdave S; O'Sullivan R; Ryan A; Konety B; Grummet JP; Frydenberg M
Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337
[TBL] [Abstract][Full Text] [Related]
34. Impact of uptake time on image quality of [
van der Sar ECA; Viol SLM; Braat AJAT; van Rooij R; Lam MGEH; de Jong HWAM; de Keizer B
Med Phys; 2023 Dec; 50(12):7619-7628. PubMed ID: 37093883
[TBL] [Abstract][Full Text] [Related]
35. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
[TBL] [Abstract][Full Text] [Related]
36. Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer.
Bodar YJL; Veerman H; Meijer D; de Bie K; van Leeuwen PJ; Donswijk ML; van Moorselaar RJA; Hendrikse NH; Boellaard R; Oprea-Lager DE; Vis AN
BJU Int; 2022 Jun; 129(6):768-776. PubMed ID: 35166426
[TBL] [Abstract][Full Text] [Related]
37. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.
Hermsen R; Wedick EBC; Vinken MJM; van Kalmthout LWM; Küsters-Vandevelde HVN; Wijers CHW; Somford DM; van Basten JA
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3929-3937. PubMed ID: 35543733
[TBL] [Abstract][Full Text] [Related]
38. A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [
Lv J; Yu H; Yin H; Shi Y; Shi H
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):919-927. PubMed ID: 37940684
[TBL] [Abstract][Full Text] [Related]
39. Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI,
Akkaya H; Dilek O; Özdemir S; Taş ZA; Öztürk İS; Gülek B
Diagn Interv Radiol; 2023 Sep; 29(5):647-655. PubMed ID: 37395389
[TBL] [Abstract][Full Text] [Related]
40. Evaluating the value of
Luo L; Zheng A; Chang R; Li Y; Gao J; Wang Z; Duan X
Cancer Imaging; 2023 Nov; 23(1):108. PubMed ID: 37924154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
